Gentian Diagnostics ASA

Share Issue/Capital Change • Jan 27, 2017

Mandatory notification of trade of primary insider

Mandatory notification of trade of primary insider

Reference is made to the stock exchange release from Gentian

Diagnostics AS ("Gentian" or the "Company") published

yesterday regarding the contemplated private placement of up

to NOK 100 million by issuance of up to 2,857,143 new shares

at NOK 35 per share (the "Private Placement").

The application period in Tranche 2 expired at 14:00 CET

today, 27 January 2017. Tranche 2 was fully subscribed and

in total 142,857 new shares were allocated at NOK 35 per

share (corresponding to NOK 4,999,995 in gross proceeds).

Total number of shares placed in Tranche 1 and Tranche 2 of

the Private Placement is hence 2,857,143, corresponding to

gross proceeds of NOK 100,000,005.

In connection with the Private Placement Tranche 2, the

following primary insider has been allocated for shares in

Gentian Diagnostics AS:

Vice President of Marketing and Sales, Catherine Townsley.

Details on the transaction:

Date of the transaction: 27.01.2017

Nummber os shares before trade: 13 760

Number of share aquired: 1 000

Number of shares after the trade: 14 760

Share price: NOK 35

Allocation of the new shares is conditional on the Private

Placement being completed. Completion of the Private

Placement is subject to, inter alia, approval of the

company's extraordinary general meeting in a meeting

expected to be held 30 January 2017.

This notification is given according to Merkur Market's

continuing obligations section 6.2.